Altimmune : 5th NASH Summit 2021 Presentation

Published: 2021-11-30 09:41:12 ET ALT

Weight Loss-

The Preferred Treatment for NASH

M. Scott Harris, MD

Chief Medical Officer

Altimmune, Inc.

5th Annual NASH Summit 30 November 2021

NASDAQ: ALT

Forward-looking statements

Safe-Harbor Statement

This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing of clinical development and funding milestones for our clinical assets as well as statements relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, and the prospects for commercializing or selling any product or drug candidates. In addition, when or if used in this presentation, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company may identify forward- looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: potential impacts due to the COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy, the timing and reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; our lack of financial resources and access to capital; clinical trials and the commercialization of proposed product candidates (such as marketing, regulatory, product liability, supply, competition, dependence on third parties and other risks); the timing of regulatory applications and the regulatory approval process; dependence on intellectual property and reimbursement and regulation. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, which are available at www.sec.gov. The statements made herein speak only as of the date stated herein, and any forward-looking statements contained herein are based on assumptions that the Company believes to be reasonable as of this date. The Company undertakes no obligation to update these statements as result of new information or future events.

CDC: OBESITY IN U.S. DRAMATICALLY INCREASING

P R E VA L E N C E O F S E L F - R E P O R T E D O B E S I T Y A M O N G U . S . A D U LT S B Y S TAT E A N D T E R R I T O R Y 1

2011

2020

1 - https://www.cdc.gov/obesity/data/prevalence-maps.html#race

3

OBESITY: SIGNIFICANT BURDEN TO HEALTHCARE SYSTEM

O P P O R T U N I T Y T O A D D R E S S M A N Y C O M O R B I D I T I E S T H R O U G H T H E T R E AT M E N T O F O B E S I T Y

IMPACT OF

OBESITY

COMORBIDITIES

1

- https://www.sciencedaily.com/releases/2019/10/191024143218.htm

4

2

- https://www.cdc.gov/obesity/adult/causes.html

3

- https://www.biospace.com/article/obesity-treatment-market-size-to-reach-usd-27-10-billion-in-2028/

OBESITY AND FATTY LIVER DISEASE

D I S E A S E S W I T H U N M E T N E E D A P P R O A C H I N G E P I D E M I C P R O P O R T I O N

US Obesity

US NAFLD Population

Population

63.7M

108M

NASH 12.7M

The treatment of obesity is the cornerstone of treating NASH and the principal co-morbidities of NASH1,2

Previous approaches to the treatment of obesity have been associated with safety concerns limiting success

The recent success of semaglutide (WegovyTM) has created a regulatory pathway for other incretin-based approaches

1Glass LM, Fed Pract 2019; 2Perazzo H, Liver Int 2017

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Altimmune Inc. published this content on 30 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 November 2021 14:40:04 UTC.